Winter 2017
RiverVest’s new Archer Seed Fund will invest pre-seed and seed funding in about 10 early-stage  biopharma companies. Investment opportunities will be sourced primarily from leading medical research institutions in St. Louis, the Midwest, and elsewhere in the U.S. 
Karen Gheesling Mullis, Ph.D., PMP, has joined RiverVest as venture partner at RiverVest's new (and second) office in St. Louis, located at the Cortex Innovation Community. Karen is leading the firm's efforts to source and conduct due diligence on investment opportunities for its new Archer Seed Fund, then oversee the development activities of the companies in which the fund invests.

RiverVest is hosting its 16th Annual Meeting for investors in St. Louis on April 11, 2017.
Portfolio News
Allakos, Inc., San Carlos, CA is a clinical stage company developing antiobodies intended to treat severe allergic and other diseases characterized by excess activity of mast cells and eosinophils.
Amplyx Pharmaceuticals, Inc., San Diego, CA, is an early-stage biopharma company developing novel, broad-spectrum antifungal agents.
Tioma Therapeutics, St. Louis, MO, is a biopharma company developing anti-CD47 antibodies for the treatment of solid tumors and hematologic cancers.
Tryton Medical, Inc., Durham, NC is a medical device company developing stents to treat coronary bifurcation lesions.
RiverVest Venture Partners® is a venture capital firm focused on identifying and shaping early-stage life science companies to create significant shareholder value. Because of its extensive operating expertise, RiverVest is able to help entrepreneurs achieve near-term objectives that position their companies for exit.